|
Market Cap | 49.94M | EPS (ttm) | - |
P/E | - | EPS this Y | -115.60% |
Forward P/E | - | EPS next Y | 48.72% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 8.27 | EPS Q/Q | 305.79% |
Dividend | - | Sales Q/Q | 97.64% |
Insider Own | 34.49% | Inst Own | 2.18% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 8.10% | Earnings | Apr 08/b |
Analyst Recom | 1.00 | Target Price | 43.00 |
Avg Volume | 316.38K | 52W Range | 4.79 - 69.80 |
|
|
|
Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom. |
|
|
|
Market Cap | 2.42M | EPS (ttm) | -0.27 |
P/E | - | EPS this Y | 48.31% |
Forward P/E | - | EPS next Y | 52.17% |
PEG | - | EPS past 5Y | 26.37% |
P/S | - | EPS next 5Y | - |
P/B | 3.36 | EPS Q/Q | 74.96% |
Dividend | - | Sales Q/Q | - |
Insider Own | 6.04% | Inst Own | 4.06% |
Insider Trans | 0.00% | Inst Trans | -85.42% |
Short Float | 1.28% | Earnings | Mar 22/b |
Analyst Recom | 1.00 | Target Price | 337.50 |
Avg Volume | 7.98K | 52W Range | 3.48 - 42.15 |
|
|
|
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA. |
|
|
|
Market Cap | 33.88M | EPS (ttm) | -2.11 |
P/E | - | EPS this Y | 45.50% |
Forward P/E | - | EPS next Y | 3.67% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -350.73% |
Dividend | - | Sales Q/Q | - |
Insider Own | 17.80% | Inst Own | 4.06% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 6.18% | Earnings | May 14/a |
Analyst Recom | 1.00 | Target Price | 50.00 |
Avg Volume | 438.26K | 52W Range | 1.90 - 12.00 |
|
|
|
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Hurvitz Chaim | Director | Aug 30 '23 | Buy | 0.29 | 70,000 | 20,125 | 570,000 | Sep 11 09:15 AM | Gorovitz Aaron | Director | Aug 30 '23 | Buy | 0.32 | 35,000 | 11,196 | 105,000 | Sep 11 09:19 AM | Javitt Jonathan C | Chief Scientist | Aug 23 '23 | Buy | 0.33 | 100,000 | 33,000 | 446,332 | Aug 24 12:14 PM | Javitt Jonathan C | Chief Scientist | Aug 22 '23 | Buy | 0.32 | 200,000 | 64,400 | 346,332 | Aug 23 09:24 AM |
|
|
| |
|
Market Cap | 1.54B | EPS (ttm) | -0.06 |
P/E | - | EPS this Y | -51.51% |
Forward P/E | 16.03 | EPS next Y | 40.24% |
PEG | - | EPS past 5Y | - |
P/S | 1.26 | EPS next 5Y | 20.00% |
P/B | 23.75 | EPS Q/Q | -399.46% |
Dividend | - | Sales Q/Q | -36.53% |
Insider Own | 2.72% | Inst Own | 94.60% |
Insider Trans | -2.94% | Inst Trans | 3.31% |
Short Float | 9.67% | Earnings | May 01/b |
Analyst Recom | 2.14 | Target Price | 14.58 |
Avg Volume | 2.16M | 52W Range | 10.49 - 32.73 |
|
|
Today | Upgrade |
Craig Hallum |
Hold → Buy |
$14 |
|
|
Extreme Networks, Inc. engages in the provision of software driven networking solutions for enterprise, data center, and service provider customers. It operates through the following geographical segments: Americas, EMEA, and APAC. Its products include Extreme Applications, Extreme Switching, Extreme Routing and Extreme Mobility. The company was founded in May 1996 and is headquartered in Morrisville, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
MEYERCORD EDWARD | PRESIDENT AND CEO | May 09 '24 | Sale | 10.63 | 50,000 | 531,370 | 1,119,724 | May 10 04:11 PM | MOTIEY KATAYOUN | Chief Legal Admin Sust Officer | Feb 15 '24 | Option Exercise | 0.00 | 9,498 | 0 | 104,405 | Feb 16 04:19 PM | MEYERCORD EDWARD | PRESIDENT AND CEO | Feb 15 '24 | Option Exercise | 0.00 | 64,727 | 0 | 1,184,942 | Feb 16 04:18 PM | MEYERCORD EDWARD | PRESIDENT AND CEO | Feb 01 '24 | Option Exercise | 6.40 | 28,443 | 182,035 | 1,158,054 | Feb 02 05:03 PM | MEYERCORD EDWARD | PRESIDENT AND CEO | Feb 01 '24 | Sale | 13.24 | 28,443 | 376,602 | 1,129,611 | Feb 02 05:03 PM |
|
|
|
|
Market Cap | 3.21M | EPS (ttm) | -8.66 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 17.42% |
P/S | 1.06 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 82.40% |
Dividend | - | Sales Q/Q | 396.78% |
Insider Own | 0.96% | Inst Own | 4.08% |
Insider Trans | 0.00% | Inst Trans | -24.87% |
Short Float | 1.21% | Earnings | Apr 16/b |
Analyst Recom | 3.00 | Target Price | 2.00 |
Avg Volume | 3.93M | 52W Range | 0.50 - 8.60 |
|
|
|
INVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL. |
|
| |
|
Market Cap | 113.57M | EPS (ttm) | 36.64 |
P/E | 0.11 | EPS this Y | -63.43% |
Forward P/E | 3.50 | EPS next Y | 14.29% |
PEG | - | EPS past 5Y | - |
P/S | 0.62 | EPS next 5Y | - |
P/B | 0.32 | EPS Q/Q | -128.98% |
Dividend | - | Sales Q/Q | -21.19% |
Insider Own | 40.03% | Inst Own | 4.66% |
Insider Trans | 0.00% | Inst Trans | 83.60% |
Short Float | 22.49% | Earnings | May 16/b |
Analyst Recom | 1.00 | Target Price | 8.00 |
Avg Volume | 488.27K | 52W Range | 1.18 - 4.08 |
|
|
|
Imperial Petroleum, Inc. operates as a ship-owning company. It provides petroleum product and crude oil seaborne transportation services. The firm offers international seaborne transportation services to oil producers, refineries and commodities traders. It has a fleet of three medium range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals, and one Aframax tanker which is used for carrying crude oil. The company was founded on May 14, 2021 and is headquartered in Athens, Greece. |
|
|
|
Market Cap | 983.90M | EPS (ttm) | -16.06 |
P/E | - | EPS this Y | 90.69% |
Forward P/E | - | EPS next Y | 84.69% |
PEG | - | EPS past 5Y | -76.81% |
P/S | 4.02 | EPS next 5Y | 13.28% |
P/B | 2.17 | EPS Q/Q | 51.57% |
Dividend | - | Sales Q/Q | -22.69% |
Insider Own | 28.90% | Inst Own | 6.03% |
Insider Trans | -0.39% | Inst Trans | - |
Short Float | 13.32% | Earnings | Feb 09/b |
Analyst Recom | 3.62 | Target Price | 6.03 |
Avg Volume | 16.00M | 52W Range | 2.76 - 19.20 |
|
|
|
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Lazzarato David Angelo | Director | Dec 29 '23 | Sale | 6.68 | 3,713 | 24,803 | 17,042 | Jan 02 06:33 PM | Yanofsky Theresa | Director | Dec 29 '23 | Sale | 6.68 | 3,697 | 24,696 | 17,501 | Jan 02 06:34 PM | Lazzarato David Angelo | Director | Nov 20 '23 | Sale | 0.81 | 38,502 | 31,187 | 207,562 | Nov 22 04:03 PM | Yanofsky Theresa | Director | Nov 20 '23 | Sale | 0.81 | 38,344 | 31,059 | 211,991 | Nov 22 04:02 PM | SCHMELING JUDY | Director | Nov 20 '23 | Sale | 0.81 | 18,481 | 14,970 | 420,541 | Nov 22 04:01 PM |
|
|
| |
|
Market Cap | 23.65M | EPS (ttm) | -11.56 |
P/E | - | EPS this Y | 37.66% |
Forward P/E | - | EPS next Y | 5.10% |
PEG | - | EPS past 5Y | -657.36% |
P/S | 27.83 | EPS next 5Y | - |
P/B | 1.08 | EPS Q/Q | 66.14% |
Dividend | - | Sales Q/Q | -96.86% |
Insider Own | 17.06% | Inst Own | 8.25% |
Insider Trans | -44.57% | Inst Trans | - |
Short Float | 3.95% | Earnings | May 14/a |
Analyst Recom | 3.00 | Target Price | 1.20 |
Avg Volume | 3.69M | 52W Range | 0.92 - 24.00 |
|
|
|
AEye, Inc. engages in the development of vision hardware, software and algorithms that act as the eyes and visual cortex of autonomous vehicles. It specializes in computer vision, autonomous driving, robotic vision, autonomous vehicles, lidar, sensor fusion, and three dimensional mapping. The company was founded by Luis C. Dussan, Ranson Wuller, Barry Behnken, and Jordan Greene in 2013 and is headquartered in Dublin, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dussan Luis | Director | Dec 01 '23 | Sale | 0.15 | 32,778 | 4,946 | 16,344,985 | Dec 01 06:07 PM | Dussan Luis | Director | Nov 30 '23 | Sale | 0.15 | 64,109 | 9,886 | 16,377,763 | Dec 01 06:07 PM | Dussan Luis | Director | Nov 29 '23 | Sale | 0.15 | 87,054 | 13,328 | 16,441,872 | Nov 29 05:54 PM | Dussan Luis | Director | Nov 28 '23 | Sale | 0.16 | 55,233 | 8,567 | 16,528,926 | Nov 29 05:54 PM | Dussan Luis | Director | Nov 27 '23 | Sale | 0.16 | 49,852 | 8,106 | 16,584,159 | Nov 27 05:35 PM |
|
|
|
|
Market Cap | 321.83M | EPS (ttm) | -3.24 |
P/E | - | EPS this Y | 22.32% |
Forward P/E | - | EPS next Y | 1.17% |
PEG | - | EPS past 5Y | -148.81% |
P/S | - | EPS next 5Y | - |
P/B | 1.05 | EPS Q/Q | 7.64% |
Dividend | - | Sales Q/Q | - |
Insider Own | 19.36% | Inst Own | 73.49% |
Insider Trans | -0.66% | Inst Trans | 7.14% |
Short Float | 14.79% | Earnings | May 09/a |
Analyst Recom | 1.67 | Target Price | 9.33 |
Avg Volume | 3.92M | 52W Range | 1.87 - 40.58 |
|
|
Today 08:00AM
|
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
(GlobeNewswire) +8.95% |
May-13-24 09:02PM
|
VTYX ALERT: Top Law Firm Bleichmar Fonti & Auld LLP Is Investigating the Directors of Ventyx Biosciences, Inc. for Potential Breaches of Fiduciary Duty; Contact the Firm for More Details
(Newsfile) |
10:37AM
|
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
(Insider Monkey) |
May-09-24 08:59PM
|
VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024
(InvestorPlace) |
04:01PM
|
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
(GlobeNewswire) |
May-02-24 04:05PM
|
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
(GlobeNewswire) |
Apr-30-24 12:00PM
|
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
(Zacks) |
Apr-17-24 08:45AM
|
NASDAQ: VTYX Lawsuit Notice: Investors who lost over $100,000 with shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) should contact the Shareholders Foundation
(GlobeNewswire) -7.98% |
05:45AM
|
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
(PR Newswire) |
Apr-15-24 01:15PM
|
Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit
(PR Newswire) |
|
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mohan Raju | CEO AND PRESIDENT | Apr 02 '24 | Sale | 5.40 | 4,312 | 23,299 | 1,578,250 | Apr 03 07:32 PM | Krueger Christopher W | CHIEF BUSINESS OFFICER | Apr 02 '24 | Sale | 5.40 | 1,651 | 8,921 | 284,999 | Apr 03 07:37 PM | Nuss John | CHIEF SCIENTIFIC OFFICER | Apr 02 '24 | Sale | 5.40 | 1,651 | 8,921 | 264,998 | Apr 03 07:33 PM | Auster Martin | CHIEF FINANCIAL OFFICER | Apr 02 '24 | Sale | 5.40 | 1,405 | 7,592 | 24,303 | Apr 03 07:30 PM | Nuss John | CHIEF SCIENTIFIC OFFICER | Mar 28 '24 | Option Exercise | 0.00 | 4,531 | 0 | 266,649 | Mar 29 06:07 PM |
|
|
|
|
Market Cap | 114.22M | EPS (ttm) | -2.45 |
P/E | - | EPS this Y | 28.45% |
Forward P/E | - | EPS next Y | 52.82% |
PEG | - | EPS past 5Y | 0.51% |
P/S | - | EPS next 5Y | 26.70% |
P/B | 1.10 | EPS Q/Q | -63.58% |
Dividend | - | Sales Q/Q | - |
Insider Own | 14.53% | Inst Own | 75.40% |
Insider Trans | 0.00% | Inst Trans | 63.92% |
Short Float | 7.39% | Earnings | May 09/a |
Analyst Recom | 2.50 | Target Price | 2.90 |
Avg Volume | 552.41K | 52W Range | 0.98 - 5.64 |
|
|
|
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA. |
|
|